What Is My Risk?

Can you access my risk? 4.5 weeks ago, things got out of control at a strip club in Michigan and I received oral sex from two strippers and also fingered them and made out with them. I’m pretty sure I’m not at too much of risk, but could you give me your opinion on what my risk is? And I have one other question. Is a 13 week test 100% conclusive as I plan to take one just to be sure. I have considered a DNA PCR test but I have read on Med Help that the test in not very accurate.

Dear Buddy, let’s start with your risk of contacting a sexually transmitted disease.

As you can imagine, many of our callers tend to be fixated on HIV infection. While we understand this, we want you to be careful not to overlook other infections that could be more likely from this exposure. If the oral sex was unprotected fellatio, then you should consider testing for chlamydia and gonorrhea.

Your risk involves exposure to saliva, vaginal secretions, and skin to skin exposure. Skin to skin exposure can result in a herpes or syphilis infection, as well as molluscum contagiosum, scabies, pubic lice and multiple other infections. All of these infections are probably more likely than man HIV infection. It is true that something like HIV can be transmitted through exposure to vaginal secretions, but the skin needs to be somehow compromised. For many, early exposure antigen testing is a great way to relieve anxiety shortly after a potential exposure. The HIV DNA PCR is a great option for people that want to avoid waiting 3 months to know their HIV status.

You mentioned that you read that the test is not very accurate, but you did not mention why they said that. Many places say that the test is not used for diagnostic procedures. This is true. Although this holds true for the antibody test as well.  In order to DIAGNOSE HIV, one must test positive on the confirmatory western blot, no matter which screening test is performed (HIV DNA PCR or HIV ELISA). Polymerase Chain Reaction (PCR) is a nobel prize winning technology, and as with any lab testing further testing may be needed to confirm a positive lab result. To address any specific concerns about the DNA PCR, we encourage you to call one of our test experts at 866-926-4669.

Herpes Simplex Virus Type 1 and Transmission

I just received the results from my STD testing and it showed positive for Herpes Simplex Virus Type 1. I haven’t had a cold sore in years. I am in a relationship with a woman and we have both been tested just to make sure. Is it possible to infect my partner by kissing or oral sex?

Yes. Herpes Simplex Virus type 1 is the virus that most commonly causes oral herpes. If you have oral herpes caused by Herpes Simplex Virus type 1, it is possible for a person to contract herpes from you through contact with your mouth.

It is more likely for your partner to contract herpes from a contact like kissing or from you performing oral sex because these contacts involve contact with mucosal tissue. This tissue is the softer, more sensitive tissue, located in areas like the lips and genital regions. These areas are considered more susceptible to herpes infection than other parts of the body. You want to know whether you are putting your partner at a greater risk for contracting herpes. You should consider that most people have oral herpes, which makes you just like most people. This means that you are not really any different than most other people your partner has kissed or had oral sex with.

As far as the probability of your partner contracting herpes, their risk for contracting herpes is going to be greater if they have no previous exposure to a herpes virus. For example, a person completely without herpes could be more likely to contract herpes from having oral sex performed on them, than a person that has previously been exposed, and therefore has some immune resistance.

Another thing to think about is that it is much more likely for your partner to have oral herpes caused by HSV-1 than not. Therefore, while your concern is admirable, most people are not as cautious, at least in regards to this situation.

LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area

HIV-1 diagnosis in babies born to seropositive mothers is one of the challenges of HIV epidemics in children. A simple, rapid protocol was developed for quantifying HIV-1 DNA in whole blood samples and was used in the ANRS French pediatric cohort in conditions of prevention of mother-to-child transmission. A quantitative HIV-1 DNA protocol (LTR real-time PCR) requiring small blood volumes was developed. First, analytical reproducibility was evaluated on 172 samples. Results obtained on blood cell pellets and Ficoll-Hypaque separated mononuclear cells were compared in 48 adult HIV-1 samples. Second, the protocol was applied to HIV-1 diagnosis in infants in parallel with plasma HIV-RNA quantitation. This prospective study was performed in children born between May 2005 and April 2007 included in the ANRS cohort. The assay showed good reproducibility. The 95% detection cut-off value was 6 copies/PCR, that is, 40 copies/10(6) leukocytes. HIV-DNA levels in whole blood were highly correlated with those obtained after Ficoll-Hypaque separation (r = 0.900, P < 0.0001). A total of 3,002 specimens from 1,135 infants were tested. The specificity of HIV-DNA and HIV-RNA assays was 100%. HIV-1 infection was diagnosed in nine infants before age 60 days. HIV-DNA levels were low, underlining the need for sensitive assays when highly active antiretroviral therapy (HAART) has been given. The performances of this HIV-DNA assay showed that it is adapted to early diagnosis in children. The results were equivalent to those of HIV-RNA assay. HIV-DNA may be used even in masked primary infection in newborns whose mothers have received HAART. J. Med. Virol. 81:217-223, 2009. (c) 2008 Wiley-Liss, Inc.

Hepatitis C RNA Quantitative Testing

The quantitative HCV RNA tests use either a process called polymerase chain reaction (PCR) or transcription-mediated amplification (TMA) or signal amplification (branched DNA). These are all “quantitative” techniques and will give an actual level of HCV RNA — a measurement of the amount of hepatitis C virus in the blood. The result will be an exact number, such as “1,215,422 IU/L.” Many people refer to the quantitative measurement as the hepatitis C “viral load”.
Explanation of test results:

There are 2 situations in which a quantitative test is useful:
The quantitative HCV RNA test is checked before a patient starts treatment.

For each patient, the result can be described as either a “high” viral load, which is usually >800,000 IU/L, or a “low” viral load, which is usually <800,000 IU/L. Knowing the viral load before starting treatment is useful because patients with “high” viral loads can have a difficult time getting the virus to become completely undetectable on treatment. Patients with “low” viral loads have a better chance of getting their virus to become completely undetectable on treatment.
The quantitative HCV RNA test is used to monitor a patient who is currently on treatment.

The response to treatment is considered good when the quantitative HCV RNA measurement drops and the virus eventually becomes completely undetectable.

Hepatitis C Virus Tests

Test Overview

Hepatitis C virus (HCV) test is a blood test that looks for proteins (antibodies) or genetic material (RNA) of the virus that causes hepatitis C. These proteins will be present in your blood if you have a hepatitis C infection now or have had one in the past. It is important to identify the type of hepatitis virus causing the infection, to prevent its spread and start the proper treatment.

HCV is spread through infected blood.

Anti-HCV antibody tests look for antibodies to HCV in the blood, indicating an HCV infection has occurred. This test cannot tell the difference between an acute or long-term infection. The enzyme immunoassay (EIA) may be the first test done to detect anti-HCV antibodies.
HCV RIBA is an additional test that detects antibodies to HCV. This test can tell whether a positive result was caused by an actual HCV infection or whether the result was a false-positive. This test may be done to double-check a positive EIA test result.
HCV RNA PCRgenetic material (RNA) testing uses polymerase chain reaction (PCR) to identify an active hepatitis C infection. The RNA can be found in a person’s blood within 1 to 2 weeks after exposure to the virus. HCV RNA testing may be done to double-check a positive result on an HCV antibody test, measure the level of virus in the blood (called viral load), or show how well a person with HCV is responding to treatment.
HCV quantitative test (also called viral load) is often used before and during treatment to find out how long treatment needs to be given and to check how well treatment is working.
HCV viral genotyping is used to find out which genotype of the HCV virus is present. HCV has 6 genotypes, and some are easier to treat than others.

There is no vaccine available to prevent hepatitis C.
Why It Is Done

Hepatitis C virus testing is done to:

Identify the type of hepatitis C virus causing the infection.
Screen people (such as doctors, dentists, and nurses) who have an increased chance of getting or spreading a hepatitis C infection.
Screen potential blood donors and donor organs to prevent the spread of hepatitis C.
Find out if a hepatitis C infection is the cause of abnormal liver function tests.

How It Is Done

The health professional taking a sample of your blood will:

Wrap an elastic band around your upper arm to stop the flow of blood. This makes the veins below the band larger so it is easier to put a needle into the vein.
Clean the needle site with alcohol.
Put the needle into the vein. More than one needle stick may be needed.
Attach a tube to the needle to fill it with blood.
Remove the band from your arm when enough blood is collected.
Put a gauze pad or cotton ball over the needle site as the needle is removed.
Put pressure on the needle site, and then put on a bandage.

How It Feels

The blood sample is taken from a vein in your arm. An elastic band is wrapped around your upper arm. It may feel tight. You may feel nothing at all from the needle, or you may feel a quick sting or pinch.
Risks

There is very little chance of a problem from having blood sample taken from a vein.

You may get a small bruise at the site. You can lower the chance of bruising by keeping pressure on the site for several minutes.
In rare cases, the vein may become swollen after the blood sample is taken. This problem is called phlebitis. A warm compress can be used several times a day to treat this.
Ongoing bleeding can be a problem for people with bleeding disorders. Aspirin, warfarin (Coumadin), and other blood-thinning medicines can make bleeding more likely. If you have bleeding or clotting problems, or if you take blood-thinning medicine, tell your doctor before your blood sample is taken.

Results

The hepatitis C virus (HCV) test is a blood test that looks for proteins (antibodies) the body makes against HCV or for the genetic material (RNA) of the hepatitis C virus.

Results of hepatitis C virus testing that show no infection are called negative. This means that no antibodies against HCV or HCV genetic material was found. Results are usually available in 5 to 7 days.
Hepatitis C virus tests
Normal (negative):    No hepatitis C antibodies are found.
No hepatitis C genetic material (RNA) is found.
Abnormal (positive):    Hepatitis C antibodies are found. A test to detect HCV RNA is needed to determine whether the infection is current or occurred in the past. If HCV RNA is found, genotyping can determine which strain of HCV is causing the infection.
Hepatitis C genetic material (RNA) is detected. This result indicates a current hepatitis C virus infection.
What Affects the Test

Many conditions can change HCV antibody levels. Your doctor will talk with you about any abnormal results that may be related to your symptoms and medical history.

Your results may need to be rechecked if you are taking some herbs or other natural products.
What To Think About

There is no vaccine at this time to prevent infections with the hepatitis C virus.
Hepatitis antibodies can take weeks to develop, so your results may be negative even though you have the early stages of an infection (false-negative).
All donated blood and organs are tested for hepatitis C before being used.
Other tests that show how well the liver is working are usually done if your doctor thinks you may have hepatitis C. These may include blood tests for bilirubin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase. For more information, see the medical tests Bilirubin, Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST).
Many states require that some types of hepatitis infections be reported to the local health department. The health department can then send out a warning to other people who may have been infected with the hepatitis virus, such as those who are close contacts of someone who has hepatitis C.

Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.

Larghi A, Tagger A, Crosignani A, Ribero ML, Bruno S, Portera G, Battezzati PM, Maggioni M, Fasola M, Zuin M, Podda M

Department of Internal Medicine, Ospedale San Paolo, Milan, Italy.

Whether sustained biochemical response and absence of serum HCV RNA in the 6-12 months following suspension of interferon-alpha (IFN-alpha) therapy reflect definitive viral clearance in patients with chronic hepatitis C virus (HCV) infection is controversial. To obtain more information on this topic, HCV RNA was sought in both liver and serum samples of 25 long-term responders who were followed for a median period of 39 months (range 21-79) after discontinuation of IFN-alpha. Liver biopsy was undertaken before and 6 to 12 months after IFN-alpha withdrawal. Liver and serum HCV RNA were tested by a nested polymerase chain reaction. Twenty-two patients (88%) tested negative for both liver and serum HCV RNA, two patients had detectable HCV RNA in both liver and serum, and one patient showed persistent HCV RNA only in the liver. Post-treatment liver histology improved markedly in all patients, including those with viral persistence. During further follow-up, biochemical remission was maintained in all patients except one in whom both serum and liver specimens remained HCV RNA positive. The data indicate that the large majority of long-term responders test negative for HCV RNA in the liver, which suggests definitive eradication of HCV RNA infection.

Healthcare Workers Exposed to HIV/AIDS

The human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS). HIV can be transmitted through the exchanging of bodily fluids including blood, semen, vaginal discharge, and breast milk. Means of transmission include sexual contact with an infected person, sharing of needles or syringes with an infected person, or through blood transfusions with infected blood. Low quantities of HIV has been found in the saliva and tears of some AIDS patients; however, contact with saliva or tears has never resulted in an HIV transmission.

Healthcare workers are often exposed to the virus at work; however, it is unlikely that they will contract the virus from a patient. Since December 2001, there have been only 57 documented reports of patient-to-worker HIV transmission, mainly due to precautionary guidelines that healthcare workers follow. The main risk of transmission for healthcare workers  is through accidental needle sticks or other injury with a contaminated instrument. However, even here the risk is small. “Researchers estimate that only about 0.0-1% or healthcare workers” contract HIV from an accidental needle stick.

This low statistic can be attributed to post-exposure prophylaxis (PEP), which can be taken immediately after exposure to reduce the risk of transmission. PEP uses antiretroviral therapy (ART) to prevent transmission, but often comes with serious side effects including dizziness, fatigue, nausea, vomiting, diarrhea and more. Current antiretroviral drugs cannot cure HIV infection, nor reduce the risk of transmitting it to someone else, but they can suppress the virus to undetectable levels in some cases. It has been estimated that PEP reduces the infection rate among healthcare workers by 79%.

Post-exposure Prophylaxis should begin immediately after the exposure, seeing as how PEP is most effective when it is initiated within two t0 four hours of exposure. The specific dosage of medication depends on a couple factors including the patient’s overall health, the severity of exposure, the availability of antiretrovirals, and if the patient has any known or possible cross-resistance to any drugs. Treatment normally lasts no less than two weeks and no longer than four. Studies show that almost a quarter of those receiving PEP stop taking the medications early because of side effects. As with all forms of treatment, it is less effective if it ends early.

HIV tests should be performed after any risky sexual behavior, even if PEP was used. Immediately after HIV enters the body antibodies are produced to fight off the infection. While these antibodies cannot completely eliminate the virus, we can use their presence to see if HIV is in the blood. Most people develop detectable antibodies within two to eight weeks; however, it may take longer in some people. Most often, the enzyme immunoassay (EIA) test is used to detect HIV antibodies. If a positive result is returned it is confirmed with a follow-up test before making a diagnosis. Typically the Western blot test is used to confirm a positive HIV result. Other testing options include DNA or RNA tests, which instead of looking for antibodies actually look for genetic material of HIV. These tests can be used for early detection of HIV.

With the combination of healthcare precautions and treatment options such as PEP, we have the ability to decrease the number of patient to worker HIV transmissions drastically.

*For the complete article please refer tohttps://aboutmyhealth.us/original-articles/

Benefits of HIV Post-Exposure Prophylaxis

HIV post-exposure prophylaxis (PEP) is commonly used among health care workers and other individuals who believe they have recently been exposed to HIV. PEP can actually prevent HIV infection in some individuals, but according to a report in the Journal of Acquired Immune Deficiency Syndromes, even when PEP fails to prevent the infection it may still have beneficial effects.

The report involved a 38-year old gay man who reported having unprotected anal sex with multiple partners in the previous 48 hours. The patient was treated with Truvada as post-exposure prophylaxis. During his treatment the patient reported more episodes of risky sex, causing his treatment to be extended. During his treatment the patient was repeatedly tested for HIV. He received a couple negative HIV results, but after repeated exposures the patient tested HIV-positive.

The patient received three viral load tests shortly after his positive HIV test result. The viral load turned out to be extremely low, and his CD4 count was high. These results were out of the ordinary for someone with an acute HIV infection, and the patient had no HIV seroconversion symptoms. Several more tests were performed on the patient and all of them returned similar findings.

The authors of the article report that the patient’s HIV infection was weaker than usual, and that this result was most likely due to the antiretroviral therapy he was receiving.

*For the complete article please refer to https://aboutmyhealth.us/original-articles/

Why Even Treated Genital Herpes Sores Boost The Risk Of HIV Infection

New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.

Scientists have uncovered details of an immune-cell environment conducive to HIV infection that persists at the location of HSV-2 genital skin lesions long after they have been treated with oral doses of the drug acyclovir and have healed and the skin appears normal. These findings are published in the advance online edition of Nature Medicine on Aug. 2.

Led by Lawrence Corey, M.D., and Jia Zhu, Ph.D., of the Fred Hutchinson Cancer Research Center and Anna Wald, M.D., M.P.H., of the University of Washington, both in Seattle, the study was funded mainly by the National Institute of Allergy and Infectious Diseases (NIAID) with support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both part of the National Institutes of Health.

“The findings of this study mark an important step toward understanding why HSV-2 infection increases the risk of acquiring HIV and why acyclovir treatment does not reduce that risk,” says NIAID Director Anthony S. Fauci, M.D. “Understanding that even treated HSV-2 infections provide a cellular environment conducive to HIV infection suggests new directions for HIV prevention research, including more powerful anti-HSV therapies and ideally an HSV-2 vaccine.”

One of the most common sexually transmitted infections worldwide, HSV-2 is associated with a two- to three-fold increased risk for HIV infection. Some HSV-2-infected people have recurring sores and breaks in genital skin, and it has been hypothesized that these lesions account for the higher risk of HIV acquisition. However, recent clinical trials, including an NIAID-funded study completed last year, demonstrated that successful treatment of such genital herpes lesions with the drug acyclovir does not reduce the risk of HIV infection posed by HSV-2 . The current study sought to understand why this is so and to test an alternative theory.

“We hypothesized that sores and breaks in the skin from HSV-2 are associated with a long-lasting immune response at those locations, and that the response consists of an influx of cells that are a perfect storm for HIV infection,” says Dr. Corey, co-director of the Vaccine and Infectious Diseases Institute at The Hutchinson Center and head of the Virology Division in the Department of Laboratory Medicine at the University of Washington. “We believe HIV gains access to these cells mainly through microscopic breaks in the skin that occur during sex.”

The research team took biopsies of genital skin tissue from eight HIV-negative men and women who were infected with HSV-2. These biopsies were taken at multiple time points: when the patients had genital herpes sores and breaks in the skin, when these lesions had healed, and at two, four and eight weeks after healing. The researchers also took biopsies from four of the patients when herpes lesions reappeared and the patients underwent treatment with oral acyclovir. The scientists continued to take biopsies at regular intervals for 20 weeks after the lesions had healed. For comparison, the investigators also took biopsies from genital tissue that did not have herpes lesions from the same patients.

Previous research has demonstrated that immune cells involved in the body’s response to infection remain at the site of genital herpes lesions even after they have healed. The scientists conducting the current study made several important findings about the nature of these immune cells. First, they found that CD4+ T cells—the cells that HIV primarily infects—populate tissue at the sites of healed genital HSV-2 lesions at concentrations 2 to 37 times greater than in unaffected genital skin. Treatment with acyclovir did not reduce this long-lasting, high concentration of HSV-2-specific CD4+ T cells at the sites of healed herpes lesions.

Second, the scientists discovered that a significant proportion of these CD4+ T cells carried CCR5 or CXCR4, the cell-surface proteins that HIV uses (in addition to CD4) to enter cells. The percentage of CD4+ T cells expressing CCR5 during acute HSV-2 infection and after healing of genital sores was twice as high in biopsies from the sites of these sores as from unaffected control skin. Moreover, the level of CCR5 expression in CD4+ T cells at the sites of healed genital herpes lesions was similar for patients who had been treated with acyclovir as for those who had not.

Third, the scientists found a significantly higher concentration of immune cells called dendritic cells with the surface protein called DC-SIGN at the sites of healed genital herpes lesions than in control tissue, whether or not the patient was treated with acyclovir. Dendritic cells with DC-SIGN ferry HIV particles to CD4+ T cells, which the virus infects. The DC-SIGN cells often were near CD4+ T cells at the sites of healed lesions—an ideal scenario for the rapid spread of HIV infection.

Finally, using biopsies from two study participants, the scientists found laboratory evidence that HIV replicates three to five times as quickly in cultured tissue from the sites of healed HSV-2 lesions than in cultured tissue from control sites.

All four of these findings help explain why people infected with HSV-2 are at greater risk of acquiring HIV than people who are not infected with HSV-2, even after successful acyclovir treatment of genital lesions.

“HSV-2 infection provides a wide surface area and long duration of time for allowing HIV access to more target cells, providing a greater chance for the initial ‘spark’ of infection,” the authors write. This spark likely ignites once HIV penetrates tiny breaks in genital skin that commonly occur during sex. “Additionally,” the authors continue, “the close proximity to DC-SIGN-expressing DCs [dendritic cells] is likely to fuel these embers and provide a mechanism for more efficient localized spread of initial infection.” The investigators conclude that reducing the HSV-2-associated risk of HIV infection will require diminishing or eliminating the long-lived immune-cell environment created by HSV-2 infection in the genital tract, ideally through an HSV vaccine. Further, they hypothesize that other sexually transmitted infections (STIs) may create similar cellular environments conducive to HIV infection, explaining why STIs in general are a risk factor for acquiring HIV.

Herpes Bites, But Sores Aren’t Cause for Shame

If Christopher Scipio has one wish for the year ahead, it’s to strip away the stigma that accompanies herpes. Then again, just as important to the herbalist and homeopath is raising awareness about natural remedies to treat the disease. He knows his stuff on both counts: Scipio has had herpes himself for 13 years.

“People are very shy talking about it,” he says on the line from his Sunshine Coast home. “They suffer feelings of shame, guilt, of feeling dirty….For some people, having herpes can feel like having leprosy.”

There are several varieties of the virus, like herpes zoster (chicken pox and shingles) and human-papillomavirus, one of the most common sexually transmitted viral infections. Then there is herpes simplex, which can cause sores around the mouth or in the genital area. The last type affects nearly one-quarter of American adults, according to this month’s issue of the University of California, Berkeley’s, Wellness Letter, and about 500,000 new cases occur each year. And it’s genital herpes that causes the most anguish.

“The psychological or emotional impact is worse than the physical effects,” Scipio says. “For people who are in relationships with someone who’s not infected, the stress of potentially infecting a partner is a prime trigger for outbreaks.

“One of my clients is a 17-year-old girl who got herpes from her first boyfriend. She’s completely traumatized. That’s the last thing you want to deal with when you’re just starting your sex life….I’m sad to report that a large number of people are now celibate or cut back on their social lives because of having herpes.”

According to Health Canada, genital herpes is most commonly spread during sex by direct contact with open sores. That includes oral sex, from cold sores on the mouth. Once you have herpes, you are infected for life. Symptoms include tingling or itching around the genitals within a week of having sex with an infected partner. That’s followed by the appearance of a cluster of tiny blisters that burst and leave painful wounds for as long as three weeks. The first outbreak often comes with or is preceded by flulike symptoms such as chills and fever. Once the sores heal, the virus retreats to nerve cells and stays dormant until the next attack.

According to the Wellness Letter, it’s not clear why the virus reemerges: “Many people believe that emotional stress brings on attacks of both genital and oral herpes, and there’s some evidence to support this.”

Scipio subscribes to the theory that stress can trigger outbreaks, a phenomenon he sees as one of virus’s positive aspects.

“It’s a very good barometer; it’s a warning sign when you’re out of balance,” he says. “If you’re not in balance, you’ll have problems. So having herpes forces you to eat healthily, to deal with stress in a constructive way, and to examine your lifestyle. It forces you to stay away from caffeine, cigarettes, too much sugar and processed foods; things you should be staying away from anyway.”

He also says he believes the virus can have a beneficial effect on your personal life. “It’s a litmus test for who really cares about you,” Scipio says. “If you’re in a relationship and you tell them you have herpes, if all of a sudden they aren’t interested anymore–or if they are still interested–it’s affirmation of their desire for you.”

Having the virus also forces carriers to be honest and to practice safe sex, he notes, adding that with a few precautions, herpes doesn’t mean people can’t have good sex lives. Using a condom is vital, even when there are no visible sores, but the areas of the skin, including the anal area, that aren’t covered by a condom aren’t protected, Health Canada states.

There’s no cure, but treatment can shorten attacks and reduce the pain of the sores.

Conventional treatment involves taking prescription antiviral drugs like Zovirax (acyclovir), Valtrex (valacyclovir), and Famvir (famciclovir). They help promote healing and suppress future outbreaks. According to a new study published in the January 1, 2004, issue of the New England Journal of Medicine, taking valacyclovir every day can cut the transmission of genital herpes by as much as 48 percent. GlaxoSmithKline, which manufactures the drug, sponsored the study.

Taking daily medication for a year or more is an approach known as suppressive therapy. The Wellness Letter states that suppressive therapy keeps herpes from recurring in 60 to 90 percent of people. “These drugs have been extensively studied and appear to be very safe, with few side effects, even if taken for years,” it says.

Scipio disagrees, arguing that prescription drugs can have side effects worse than the illness they’re supposed to fight. When he starting taking pharmaceuticals years ago, he found himself experiencing migraine headaches for the first time in his life. Scipio says antivirals do have a place in herpes treatment, particularly among those who have just been diagnosed and need some time to adjust to the shock, but he notes the drugs are costly, as much as $200 a month.

He has developed a protocol consisting of herbs and homeopathic agents that he claims is effective and inexpensive. Each client’s regimen is different, but he generally suggests combining internal and topical remedies. The most common herbs he uses include lemon balm, olive leaf, and desert parsley. He sometimes incorporates Bach Flower Essences, which he says can help people deal with emotional strain. While Scipio is convinced, many conventional health professionals would likely argue that the efficacy of herbal substances to treat herpes isn’t proven, and that just because something is natural doesn’t mean it’s safe.

Scipio offers regular clinics around the Lower Mainland, including in Vancouver (on the 14th of every month). He also offers an on-line clinic which he says appeals to many because it’s private. (For details, go to his Web site at www.natropractica.com/.)

Although Scipio understands people’s desire for secrecy, he hopes that will change.

“I counsel people to make peace with the disease,” he says. “I encourage people not to be ashamed and to have the courage to speak out, to not feel like a leper.”

Categories